Loading...

FITC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_FITC_102110
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
  • 53-6.7_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100705 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100706 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  2. Liu J, et al. 2019. Immunity. 50:600. PubMed
  3. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  4. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  5. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  6. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  7. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  8. Milanovic M, et al. 2021. Cancer Res. 81:426. PubMed
  9. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  10. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  11. Martin-Martin I, et al. 2022. Cell Rep. 39:110648. PubMed
  12. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  13. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  14. Chowdhury S, et al. 2022. Cancer Res. 82:2640. PubMed
  15. Tessaro FHG, et al. 2022. Cell Rep. 39:110977. PubMed
  16. Liu W, et al. 2022. Biomedicines. 10: . PubMed
  17. Deng P, et al. 2022. J Clin Invest. 132: . PubMed
  18. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  19. Li J, et al. 2022. Front Immunol. 13:1043484. PubMed
  20. Roy S, et al. 2022. Am J Cancer Res. 12:4977. PubMed
  21. Weng S, et al. 2022. Front Immunol. 13:1025931. PubMed
  22. Ding L, et al. 2023. J Clin Invest. 133: . PubMed
  23. Choi H, et al. 2023. J Nanobiotechnology. 21:5. PubMed
  24. Wang L, et al. 2022. Nutrients. 15: . PubMed
  25. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  26. Elliot TAE, et al. 2022. Discov Immunol. 1:kyac009. PubMed
  27. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  28. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  29. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  30. Milanovic M, et al. 2021. J Immunol. 206:1228. PubMed
  31. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  32. Wei J, et al. 2022. Cancer Prev Res (Phila). 15:285. PubMed
  33. Shen JZ, et al. 2022. Mol Cell. 82:1123. PubMed
  34. Friedman D, et al. 2022. J Immunol. 208:1845. PubMed
  35. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  36. Yao RQ, et al. 2022. Theranostics. 12:4606. PubMed
  37. Lee KM, et al. 2022. Cancer Immunol Res. 10:829. PubMed
  38. Puth S, et al. 2022. Biomaterials. 286:121542. PubMed
  39. Alghamri MS, et al. 2022. ACS Nano. 16:8729. PubMed
  40. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  41. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  42. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  43. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  44. Ma X, et al. 2023. Nat Commun. 14:1606. PubMed
  45. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  46. Li D, et al. 2023. Ann Med. 55:2189295. PubMed
  47. Bhatia V, et al. 2023. Nat Commun. 14:2041. PubMed
  48. Chen F, et al. 2023. Acta Biomater. 164:387. PubMed
  49. Li Y, et al. 2023. Front Cell Infect Microbiol. 13:1117230. PubMed
  50. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  51. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  52. Park HJ, et al. 2023. NPJ Vaccines. 8:84. PubMed
  53. Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed
  54. Pagano G, et al. 2023. Haematologica. . PubMed
  55. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  56. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  57. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  58. Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed
  59. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  60. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  61. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  62. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  63. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  64. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  65. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  66. Paschall A, et al. 2015. J Immunol. 194: 2369-2379. PubMed
  67. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  68. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  69. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  70. Apte S, et al. 2010. J Immunol. 185:998. PubMed
  71. Gotoh K et al. 2018. Cell reports. 25(7):1800-1815 . PubMed
  72. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  73. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  74. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  75. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  76. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  77. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  78. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
  79. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  80. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  81. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  82. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  83. Morales D, et al. 2015. J Virol. 89:337. PubMed
  84. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  85. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  86. Okamoto T, et al. 2020. Cancer Res. 3580:80. PubMed
  87. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  88. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  89. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  90. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  91. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  92. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  93. Wu K, et al. 2021. Aging (Albany NY). 13:. PubMed
  94. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  95. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  96. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  97. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  98. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  99. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  100. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  101. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  102. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  103. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  104. Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed
  105. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  106. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  107. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  108. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  109. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  110. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  111. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  112. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  113. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  114. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  115. Xiao P, et al. 2019. J Exp Med. 216:337. PubMed
  116. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  117. Li Y, et al. 2019. Sci Rep. 9:6932. PubMed
  118. Wu J, et al. 2020. Immunity. 53:115. PubMed
  119. Köchl R, et al. 2020. Elife. 9:00. PubMed
  120. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  121. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  122. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  123. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  124. Webster P, et al. 2018. Nat Commun. 9:2649. PubMed
  125. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  126. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  127. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  128. Drees J, et al. 2015. Anticancer Res. 35:843. PubMed
  129. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  130. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  131. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  132. Crowe JL, et al. 2020. Proc Natl Acad Sci U S A. 22953:117. PubMed
  133. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  134. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  135. Wan X, et al. 2018. Nature. 560:107. PubMed
  136. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  137. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  138. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  139. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  140. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  141. Yang J, et al. 2020. Nature. 586:572. PubMed
  142. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  143. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  144. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  145. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  146. Fang Y, et al. 2019. Aging (Albany NY). 11:4910. PubMed
  147. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  148. Du J, et al. 2018. AMB Express. 8:158. PubMed
  149. Holman P, et al. 2005. J Immunol. 174:3986. PubMed
  150. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  151. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  152. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  153. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  154. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  155. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  156. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  157. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  158. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  159. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  160. Nikolos F, et al. 2022. Nat Commun. 13:1487. PubMed
  161. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  162. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  163. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  164. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  165. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  166. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  167. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  168. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  169. Jin C, et al. 2022. Oncoimmunology. 11:2099642. PubMed
  170. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  171. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  172. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  173. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  174. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  175. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  176. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  177. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  178. Riedl P, et al. 2009. J Immunol. 183:370. PubMed
  179. Wang L, et al. 2015. Cancer Immunol Res. 3: 1030-1041. PubMed
  180. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  181. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
  182. Zhan L, et al. 2022. Cancer Lett. 529:37. PubMed
  183. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  184. Dulken BW, et al. 2019. Nature. 571:205. PubMed
  185. Hu Z, et al. 2020. PLoS One. 15:e0228339. PubMed
  186. Ibrahim ML, et al. 2018. Cell Rep. 25:3036. PubMed
  187. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  188. Kvell K, et al. 2014. Immunobiology. 219:644. PubMed
  189. Feng D, et al. 2022. Nat Commun. 13:5554. PubMed
  190. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  191. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  192. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  193. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  194. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  195. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  196. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  197. Panigrahy D, et al. 2019. J Clin Invest. 130:2964. PubMed
  198. Shen L, et al. 2015. Cancer Immunol Res. 3:136. PubMed
  199. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  200. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  201. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  202. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  203. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  204. Wu P, et al. 2020. Cancer Immunol Res. 8:1470. PubMed
  205. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  206. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  207. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  208. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  209. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  210. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  211. Ren Y, et al. 2021. Nat Commun. 12:5405. PubMed
  212. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
  213. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  214. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  215. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  216. Royzman D, et al. 2019. Front Immunol. 10:633. PubMed
  217. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  218. Petriv N, et al. 2021. Oncoimmunology. 10:1874159. PubMed
  219. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  220. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  221. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  222. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  223. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  224. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  225. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  226. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  227. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  228. Li H, et al. 2022. iScience. 25:104481. PubMed
  229. Wang X, et al. 2022. Elife. 11:. PubMed
  230. Su M, et al. 2018. Immunol Cell Biol. 9:2448. PubMed
  231. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  232. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  233. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  234. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  235. D'Cruz L, et al. 2014. J Immunol. 192:2227. PubMed
  236. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  237. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  238. Wen X, et al. 2021. World J Gastroenterol. 27:2834. PubMed
  239. Wang K, et al. 2021. Nat Commun. 12:4558. PubMed
  240. Zhi Y, et al. 2020. Int J Mol Med. 45:1327. PubMed
  241. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  242. Xie L, et al. 2020. Infect Immun. :88. PubMed
  243. Hayashi K, et al. 2020. Nat Commun. 4.832638889. PubMed
  244. Schlecker E, et al. 2012. J Immunol. 189:5602. PubMed
  245. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  246. Ying B, et al. 2022. Sci Transl Med. 14:eabm3302. PubMed
  247. Lee S, et al. 2021. Autophagy. 18:1062. PubMed
  248. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  249. Akhtar MN, et al. 2020. PLoS Pathog. 16:e1009136. PubMed
  250. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  251. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  252. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
RRID
AB_312744 (BioLegend Cat. No. 100705)
AB_312744 (BioLegend Cat. No. 100706)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD8alpha
Specificity Alt (DOES NOT SHOW ON TDS):
CD8a
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account